Sitagliptin Phosphate 

• Sitagliptin is the first antidiabetic agent from the class of dipeptidyl peptidase-4 enzyme ¹
• Approved by the US Food and Drug Administration (FDA) for use with diet and exercise to improve glycemic control in adult patients with type 2 diabetes. ¹
• Sitagliptin monotherapy improved indices of glycemic control compared to placebo and was generally well-tolerated in patients with type 2 diabetes.²
• It not only improves blood glucose control but also body weight, blood pressure and lipid profile in type 2 diabetic hyperlipidaemia patients.³
• Reduced postprandial plasma levels of TG-rich lipoproteins of both intestinal and hepatic origin.⁴
• Works by increasing incretin hormone levels, reducing circulating plasma FFA concentrations and improving insulin sensitivity and β-cell function.⁴